In the last trading session, 1.63 million Immunome Inc (NASDAQ:IMNM) shares changed hands as the company’s beta touched 1.92. With the company’s per share price at $11.08 changed hands at $0.76 or 7.36% during last session, the market valuation stood at $906.03M. IMNM’s last price was a discount, traded about -179.42% off its 52-week high of $30.96. The share price had its 52-week low at $8.97, which suggests the last value was 19.04% up since then. When we look at Immunome Inc’s average trading volume, we note the 10-day average is 1.32 million shares, with the 3-month average coming to 956.36K.
Analysts gave the Immunome Inc (IMNM) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IMNM as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Immunome Inc’s EPS for the current quarter is expected to be -0.67.
Immunome Inc (NASDAQ:IMNM) trade information
Instantly IMNM was in green as seen at the end of in last trading. With action 19.91%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 4.33%, with the 5-day performance at 19.91% in the green. However, in the 30-day time frame, Immunome Inc (NASDAQ:IMNM) is 5.22% up. Looking at the short shares, we see there were 10.54 million shares sold at short interest cover period of 12.51 days.
The consensus price target for the stock as assigned by Wall Street analysts is 23, meaning bulls need an upside of 51.83% from its current market value. According to analyst projections, IMNM’s forecast low is 23 with 23 as the target high. To hit the forecast high, the stock’s price needs a -107.58% plunge from its current level, while the stock would need to soar -107.58% for it to hit the projected low.
Immunome Inc (IMNM) estimates and forecasts
Data shows that the Immunome Inc share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -19.65% over the past 6 months, a -242.75% in annual growth rate that is considerably lower than the industry average of 15.90%. Year-over-year growth is forecast to reach -32.90% down from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 3.16M. 5 analysts are of the opinion that Immunome Inc’s revenue for the current quarter will be 618.8k. The company’s revenue for the corresponding quarters a year ago was 3.83M and 1.03M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -17.51%. The estimates for the next quarter sales put growth at -39.86%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -48.48%. The 2025 estimates are for Immunome Inc earnings to increase by 17.82%, but the outlook for the next 5-year period is at 15.77% per year.
IMNM Dividends
Immunome Inc is expected to release its next quarterly earnings report in March.
Immunome Inc (NASDAQ:IMNM)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 13.29% of Immunome Inc shares while 65.11% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 75.09%. There are 65.11% institutions holding the Immunome Inc stock share, with REDMILE GROUP, LLC the top institutional holder. As of 2024-06-30, the company held 8.1579% of the shares, roughly 4.89 million IMNM shares worth $59.16 million.
FMR LLC holds the second largest percentage of outstanding shares, with 7.0257% or 4.21 million shares worth $50.95 million as of 2024-06-30.
